Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obagi Medical
Financials
Valeant shares up 16% after Q3 report on turnaround efforts
Valeant's third-quarter results provided a welcome dose of good news as the company works to execute its lengthy turnaround.
Eric Sagonowsky
Nov 7, 2017 11:51am
Valeant trades $1B for 6% royalty on a drug that's not selling
Nov 6, 2017 11:16am
Valeant's debt-fueled castoffs continue with Obagi sale
Jul 17, 2017 11:57am
Valeant CEO won't say 'never' to selling Bausch & Lomb
Sep 8, 2016 9:42am